Pluristem Therapeutics Inc. (PSTI) - 10-K Summary
Business Context and Reporting Period
Company: Pluristem Therapeutics Inc. (Pluristem)
Filing Type: Form 10-K (Annual Report)
Period Ended: June 30, 2011
Business Overview: Pluristem is a development-stage bio-therapeutic company developing standardized cell therapy products derived from human placenta (PLX cells) for the treatment of life-threatening diseases. The company utilizes a proprietary 3D manufacturing process (PluriX) to produce clinical-grade cells. Primary indications include Peripheral Artery Disease (PAD), Critical Limb Ischemia (CLI), and Pulmonary Arterial Hypertension (PAH). The company has no commercial product sales and relies on equity financing and grants.
Key Financial Metrics (Year Ended June 30, 2011)
| Metric | 2011 (in thousands) | 2010 (in thousands) |
|---|---|---|
| Revenue | $0 | $0 |
| Net Loss | $(10,848) | $(7,453) |
| Loss Per Share (Basic & Diluted) | $(0.35) | $(0.44) |
| Research & Development Expenses (Net) | $6,629 | $4,301 |
| General & Administrative Expenses | $4,485 | $3,138 |
| Cash and Cash Equivalents (Ending) | $42,829 | $1,583 |
| Working Capital | $41,279 | $2,324 |
| Accumulated Deficit | $(50,953) | $(40,105) |
Note: Financial statements are presented in thousands of U.S. Dollars.
Material Changes vs. Prior Period
- Liquidity Surge: Cash and cash equivalents increased by approximately $41.2 million (from $1.6M to $42.8M) primarily due to a firm commitment underwritten public offering in February 2011 raising approximately $38 million and an October 2010 offering raising approximately $5 million.
- Increased Operating Loss: Net loss increased by 45% to $10.8 million, driven by a 54% increase in net R&D expenses and a 43% increase in G&A expenses. Increases were attributed to higher stock-based compensation, salaries, and lab materials.
- Financial Income: Shifted from a $14,000 expense in 2010 to $266,000 income in 2011 due to interest earned on significantly higher bank deposits.
- Strategic Partnership: Entered into an exclusive license agreement with United Therapeutics Corporation (United) in June 2011 for the development of a PAH treatment, securing a $7 million upfront payment (received August 2011) and potential milestone payments totaling up to $37.5 million.
Guidance, Outlook, and Risks
Outlook: Management does not expect to generate product sales revenue in the next 12 months, estimating products will not be ready for sale for at least three years. Operating expenses are expected to increase significantly in fiscal 2012 due to Phase II/III clinical trials and the construction of a new GMP manufacturing facility. Management believes current funds are sufficient to operate until approximately the end of fiscal 2014, though additional fundraising may be required.
Key Risks:
- Development Stage: No established source of revenue; profitability depends entirely on successful commercialization of cell therapy products.
- Regulatory Approval: Products require FDA and EMA approval; failure to demonstrate safety and efficacy in clinical trials could halt operations.
- Capital Requirements: Continued need for equity financing or grants to fund operations; inability to raise capital could force cessation of operations.
- Intellectual Property: Reliance on patents and trade secrets; risk of invalidation or infringement claims.
- Geopolitical: Principal R&D facilities are in Israel, exposing the company to regional political and military instability.
Investor Verification Checklist
- Cash Runway: Verify the sufficiency of the $42.8M cash balance against projected burn rates for upcoming Phase II/III trials and new facility construction.
- United Therapeutics Agreement: Confirm the receipt of the $7M upfront payment and the specific regulatory milestones required for the $37.5M in potential future payments.
- Clinical Trial Progress: Monitor enrollment and safety data for the multinational Phase II study in Intermittent Claudication (IC) and the Phase II/III pivotal study in Critical Limb Ischemia (CLI).
- Manufacturing Capacity: Track the timeline for the new GMP facility in Haifa, Israel, scheduled to commence leasing in January 2012.
- Dilution Risk: Assess the impact of outstanding warrants (approx. 16.5M) and options (approx. 2.5M) on future share count and potential dilution from future capital raises.